Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...

While Tapentadol is a serious habit-forming opioid-based drug, Pregabalin has become a headache in Punjab as it is ...

The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXtm (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal ...

In the Opportunity Research report, analyst Rob Goldman reviews clinical and preclinical data on OKYO's lead candidate, the Company's inherent first-mover opportunities in the industry, upcoming ...

Chronic pain is a global health challenge, with current treatment options often limited by side effects, addiction risk, and diminished effectiveness over time. In a new study, Yale researchers ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigin ...

Chromocell Therapeutics Co. (NYSE:CHRO – Get Free Report)’s share price traded down 10.6% during mid-day trading on Wednesday . The company traded as low as $2.11 and last traded at $2.20. 105,552 ...

Explore how chemotherapy causes peripheral neuropathy in 40% of cancer patients. Learn about the risk factors and the need ...

The University of Cincinnati and its affiliates reached $740 million in research expenditures in 2024, a 6% increase over the previous year and a ...